Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Joe McCracken, global head of business development & licensing for Roche AG, has a unique perspective on dealmaking, filtered through the lens of a career that has spanned from biotech to Big Pharma, from the U.S. West Coast to Japan to Nutley, New Jersey.

You may also be interested in...



In Pursuit Of Greener Pastures, Roche Looks Toward China, Away From Europe

In contrast to Europe, China sees the life sciences industry as an engine of innovation, not a cost factor, Roche CEO Severin Schwan says.

Roche Global Head of Business Development & Licensing Joe McCracken On Searching For Innovative Deals In Asia: An Interview With PharmAsia News (Part 1 of 2)

Joe McCracken, global head of business development & licensing for Roche AG, has a unique perspective on dealmaking, filtered through the lens of a career that has spanned from biotech to Big Pharma, from the U.S. West Coast to Japan to Nutley, New Jersey.

As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?

SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC076755

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel